Shape 22 Experience

High-Sensitivity Troponin I Assay

Request more info
Expert research

For chest pain patients, waiting even minutes in the emergency department can feel like an eternity. Clinicians need tools to help manage these patients, while improving clinical and operational outcomes. Those tools must be expertly designed, research proven diagnostic solutions, capable of meeting clinical performance demands that are continuously evolving.

Having a high-sensitivity troponin I assay that delivers actionable results in minutes can help clinicians manage chest pain patients with increased speed, insight and confidence:

  • Offer improved cardiac patient care with a proven true high-sensitivity troponin I assay that meets the current AACC Academy/IFCC C-CB guideline recommendations1–4
  • Have confidence in patient results at the low end of the assay range with precision that provides the ability to measure slight, yet critical, changes between serial troponin I values
  • Obtain reliable results from a proven, trusted technology coupled with three new monoclonal antibodies
The Atellica® Solution’s streamlined STAT process has been shown to deliver actionable high-sensitivity troponin I results in 10 minutes.

The Atellica® Solution’s streamlined STAT process has been shown to deliver actionable high-sensitivity troponin I results in 10 minutes.

High-sensitivity Troponin I, BNP and NT-proBNP* with results in minutes

Siemens Healthineers is proud to offer high-sensitivity troponin I across multiple systems, including the Atellica® IM Analyzer, ADVIA Centaur® System, Dimension® EXL™ Integrated Systems, and Dimension Vista® Intelligent Lab Systems.

*NT-proBNP not available for sale in the U.S.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.

Over the past 20 years the analytical sensitivity and precision of cardiac troponin (cTn) assays have improved for very low cTn concentrations. Compared to traditional cTn assays, high-sensitivity troponin I (hs-cTnI) assays can detect lower levels of troponin and smaller changes to a patient’s troponin levels, which may be an early indication of AMI.

A new literature compendium features recent articles offering guidance on the use of hs-cTnI assays, including sex-specific cutoffs, serial testing, and reporting units. These studies show that the Siemens Healthineers high-sensitivity troponin I assays are proven, true high-sensitivity cardiac troponin I assays that provide fast, accurate, and actionable test results.

View literature compendium (US)
View literature compendium (Outside the US)

Collaboration Between Laboratory and Clinical Practice*

We are pleased to offer an exciting opportunity to hear from two globally recognized cardiac key opinion leaders, Professor Fred Apple and Professor Nicholas Mills as they discuss fast protocol strategies and evidence-based literature that supports implementation of high-sensitivity troponin testing in clinical practice. In addition, a thorough review of the controversial 2020 ESC NSTEMI guidelines and the NICE guidelines are provided.

Session Description:

  • Review evidence-based literature that leads to implementation of high-sensitivity cardiac troponin testing into clinical practice
  • Help healthcare providers understand diagnostic strategies using a high-sensitivity cardiac troponin assay
  • Discuss the latest guidelines (ESC, NICE) pertaining to their interpretation perspectives

Fred Apple, PhD
Co-Director Clinical & Forensic Toxicology Laboratory;
Professor, Laboratory Medicine & Pathology
Hennepin County Medical Center & University of Minnesota

Nick Mills, PhD
Consultant Interventional Cardiologist & Chair of Cardiology
Royal Infirmary of Edinburgh, Scotland & University of Edinburgh